{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:45:11Z","timestamp":1793918711060,"version":"4.8.0"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-04618-7","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T07:25:43Z","timestamp":1770103543000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Probiotics as emerging adjuncts in metabolic associated fatty liver disease therapy-a systemic review"],"prefix":"10.1186","volume":"26","author":[{"given":"Radha Samyuktha Reddy","family":"Narem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vani","family":"Mathakala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Tejaswi","family":"Sallabathula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaya Lakshmi","family":"Peddiboyina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8838-3605","authenticated-orcid":false,"given":"Uma Maheswari devi","family":"Palempalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"4618_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.bcp.2017.04.014","volume":"136","author":"X Feng","year":"2017","unstructured":"Feng X, Yu W, Li X, Liu H, Cheng W, Hu J, et al. Apigenin, a modulator of PPAR\u03b3, attenuates HFD-induced NAFLD by regulating hepatocyte lipid metabolism and oxidative stress via Nrf2 activation. Biochem Pharmacol. 2017;136:136\u201349. https:\/\/doi.org\/10.1016\/j.bcp.2017.04.014.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"4618_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7570\/jomes23052","volume":"32","author":"WK Chan","year":"2023","unstructured":"Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review. J Obes Metab Syndr. 2023;32(3):197\u2013213. https:\/\/doi.org\/10.7570\/jomes23052.","journal-title":"J Obes Metab Syndr"},{"key":"4618_CR3","doi-asserted-by":"publisher","unstructured":"Li D, Yao H, Du L, Zeng X, Xiao Q. Thallium(I and III) exposure leads to liver damage and disorders of fatty acid metabolism in mice chemosphere. 2022;135618. https:\/\/doi.org\/10.1016\/j.chemosphere.2022.135618.","DOI":"10.1016\/j.chemosphere.2022.135618"},{"issue":"13","key":"4618_CR4","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.3748\/wjg.v21.i13.3777","volume":"21","author":"Y Takahashi","year":"2015","unstructured":"Takahashi Y, Sugimoto K, Inui H, Fukusato T. Current pharmacological therapies for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. World J Gastroenterol. 2015;21(13):3777\u201385. https:\/\/doi.org\/10.3748\/wjg.v21.i13.3777.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"4618_CR5","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3390\/microorganisms9050957","volume":"9","author":"T Hrncir","year":"2021","unstructured":"Hrncir T, Hrncirova L, Kverka M, Hromadka R, Machova V, Trckova E, et al. Gut microbiota and NAFLD: pathogenetic mechanisms, microbiota signatures, and therapeutic interventions. Microorganisms. 2021;9(5):957. https:\/\/doi.org\/10.3390\/microorganisms9050957.","journal-title":"Microorganisms"},{"issue":"10","key":"4618_CR6","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"13","author":"R Loomba","year":"2021","unstructured":"Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;13(10):2537\u201364. https:\/\/doi.org\/10.1016\/j.cell.2021.04.015.","journal-title":"Cell"},{"key":"4618_CR7","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMra1503519","volume":"377","author":"AM Diehl","year":"2017","unstructured":"Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med. 2017;377:2063\u201372.","journal-title":"N Engl J Med"},{"key":"4618_CR8","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","volume":"114","author":"CP Day","year":"1998","unstructured":"Day CP, James OF. Steatohepatitis: A tale of two \u201chits\u201d? Gastroenterology. 1998;114:842\u20135.","journal-title":"Gastroenterology"},{"key":"4618_CR9","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.atherosclerosis.2019.01.029","volume":"282","author":"RD Santos","year":"2019","unstructured":"Santos RD, Valenti L, Romeo S. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. Atherosclerosis. 2019;282:110\u201320.","journal-title":"Atherosclerosis"},{"key":"4618_CR10","doi-asserted-by":"publisher","first-page":"44612","DOI":"10.1038\/srep44612","volume":"7","author":"W Luo","year":"2017","unstructured":"Luo W, Xu Q, Wang Q, Wu H, Hua J. Effect of modulation of PPAR-\u03b3 activity on Kupffer cells M1\/M2 polarization in the development of non-alcoholic fatty liver disease. Sci Rep. 2017;7:44612. https:\/\/doi.org\/10.1038\/srep44612.","journal-title":"Sci Rep"},{"issue":"5","key":"4618_CR11","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/hep.24001","volume":"52","author":"H Tilg","year":"2010","unstructured":"Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52(5):1836\u201346. https:\/\/doi.org\/10.1002\/hep.24001.","journal-title":"Hepatology"},{"issue":"3","key":"4618_CR12","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1053\/j.gastro.2006.05.054","volume":"131","author":"H Tilg","year":"2006","unstructured":"Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology. 2006;131(3):934\u201345. https:\/\/doi.org\/10.1053\/j.gastro.2006.05.054.","journal-title":"Gastroenterology"},{"issue":"9","key":"4618_CR13","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41419-020-03003-w","volume":"11","author":"P Rada","year":"2020","unstructured":"Rada P, Gonz\u00e1lez-Rodr\u00edguez \u00c1, Garc\u00eda-Monz\u00f3n C, Valverde \u00c1M. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver? Cell Death Dis. 2020;11(9):802. https:\/\/doi.org\/10.1038\/s41419-020-03003-w.","journal-title":"Cell Death Dis"},{"issue":"5","key":"4618_CR14","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.cmet.2015.04.004","volume":"21","author":"C Koliaki","year":"2015","unstructured":"Koliaki C, Szendroedi J, Kaul K, Jelenik T, Nowotny P, Jankowiak F, et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab. 2015;21(5):739\u201346. https:\/\/doi.org\/10.1016\/j.cmet.2015.04.004.","journal-title":"Cell Metab"},{"key":"4618_CR15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2147\/HMER.S188991","volume":"11","author":"S Ganguli","year":"2019","unstructured":"Ganguli S, DeLeeuw P, Satapathy SK. A review of current and upcoming treatment modalities in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Hepat Med. 2019;11:159\u201378. https:\/\/doi.org\/10.2147\/HMER.S188991.","journal-title":"Hepat Med"},{"key":"4618_CR16","doi-asserted-by":"publisher","first-page":"e95354","DOI":"10.1172\/jci.insight.95354","volume":"2","author":"T Greuter","year":"2017","unstructured":"Greuter T, Malhi H, Gores GJ, et al. Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis. JCI Insight. 2017;2:e95354.","journal-title":"JCI Insight"},{"issue":"6","key":"4618_CR17","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s11684-018-0645-9","volume":"12","author":"R Han","year":"2018","unstructured":"Han R, Ma J, Li H. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota. Front Med. 2018;12(6):645\u201357. https:\/\/doi.org\/10.1007\/s11684-018-0645-9.","journal-title":"Front Med"},{"issue":"7","key":"4618_CR18","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1053\/j.gastro.2020.01.049","volume":"158","author":"J Aron-Wisnewsky","year":"2020","unstructured":"Aron-Wisnewsky J, Warmbrunn MV, Nieuwdorp M, Cl\u00e9ment K. Nonalcoholic fatty liver disease: modulating gut microbiota to improve severity? Gastroenterology. 2020;158(7):1881\u201398. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.049.","journal-title":"Gastroenterology"},{"issue":"3","key":"4618_CR19","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ecl.2023.01.004","volume":"52","author":"TM Barber","year":"2023","unstructured":"Barber TM, Hanson P, Weickert MO. Metabolic-associated fatty liver disease and the gut microbiota. Endocrinol Metab Clin North Am. 2023;52(3):485\u201396. https:\/\/doi.org\/10.1016\/j.ecl.2023.01.004.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"5","key":"4618_CR20","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.3390\/microorganisms12051020","volume":"12","author":"T Wu","year":"2024","unstructured":"Wu T, Zeng Z, Yu Y. Role of probiotics in gut microbiome and metabolome in non-alcoholic fatty liver disease mouse model: a comparative study. Microorganisms. 2024;12(5):1020. https:\/\/doi.org\/10.3390\/microorganisms12051020.","journal-title":"Microorganisms"},{"issue":"11","key":"4618_CR21","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/j.1440-1746.2004.03446.x","volume":"19","author":"K Madan","year":"2004","unstructured":"Madan K, Batra Y, Panda SK, et al. Role of polymerase chain reaction and liver biopsy in the evaluation of patients with asymptomatic transaminitis: implications in diagnostic approach. J Gastroenterol Hepatol. 2004;19(11):1291\u20139. https:\/\/doi.org\/10.1111\/j.1440-1746.2004.03446.x.","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"4618_CR22","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","volume":"148","author":"RJ Wong","year":"2015","unstructured":"Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547\u201355. https:\/\/doi.org\/10.1053\/j.gastro.2014.11.039.","journal-title":"Gastroenterology"},{"issue":"4","key":"4618_CR23","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335\u201347. https:\/\/doi.org\/10.1097\/HEP.0000000000000004.","journal-title":"Hepatology"},{"issue":"4","key":"4618_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jhepr.2019.08.002","volume":"1","author":"S Albhaisi","year":"2019","unstructured":"Albhaisi S, Chowdhury A, Sanyal AJ. Non-alcoholic fatty liver disease in lean individuals. JHEP Rep. 2019;1(4):329\u201341. https:\/\/doi.org\/10.1016\/j.jhepr.2019.08.002.","journal-title":"JHEP Rep"},{"issue":"8","key":"4618_CR25","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","volume":"5","author":"Q Ye","year":"2020","unstructured":"Ye Q, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(8):739\u201352. https:\/\/doi.org\/10.1016\/S2468-1253(20)30077-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4618_CR26","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/j.1440-1746.2010.06443.x","volume":"26","author":"JH Tabibian","year":"2011","unstructured":"Tabibian JH, Lazo M, Durazo FA, Yeh H-C, Tong MJ, Clark JM. Nonalcoholic fatty liver disease across ethno-racial groups: do Asian-American adults represent a new at-risk population? J Gastroenterol Hepatol. 2011;26:501\u20139. https:\/\/doi.org\/10.1111\/j.1440-1746.2010.06443.x.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"4618_CR27","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1055\/s-0038-1677517","volume":"39","author":"R Younes","year":"2019","unstructured":"Younes R, Bugianesi E. Nash in lean individuals. Semin Liver Dis. 2019;39(1):86\u201395. https:\/\/doi.org\/10.1055\/s-0038-1677517.","journal-title":"Semin Liver Dis"},{"issue":"10","key":"4618_CR28","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1097\/MEG.0b013e32835643f1","volume":"24","author":"NC Nayak","year":"2012","unstructured":"Nayak NC, Jain D, Vasdev N, Gulwani H, Saigal S, Soin A. Etiologic types of end-stage chronic liver disease in adults: analysis of prevalence and their temporal changes from a study on native liver explants. Eur J Gastroenterol Hepatol. 2012;24(10):1199\u2013208. https:\/\/doi.org\/10.1097\/MEG.0b013e32835643f1.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"4618_CR29","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","volume":"72","author":"A Albillos","year":"2020","unstructured":"Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy. J Hepatol. 2020;72(3):558\u201377. https:\/\/doi.org\/10.1016\/j.jhep.2019.10.003.","journal-title":"J Hepatol"},{"issue":"10","key":"4618_CR30","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"L Rohit","year":"2021","unstructured":"Rohit L, Scott LF, Gerald IS. Mechanisms and disease consequences of non-alcoholic fatty liver disease. Cell. 2021;184(10):2537\u201364. https:\/\/doi.org\/10.1016\/j.cell.2021.04.015.","journal-title":"Cell"},{"key":"4618_CR31","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1038\/s41467-019-09455-9","volume":"10","author":"C Caussy","year":"2019","unstructured":"Caussy C, Tripathi A, Humphrey G, Bassirian S, Singh S, Faulkner C, et al. A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. Nat Commun. 2019;10:1406. https:\/\/doi.org\/10.1038\/s41467-019-09455-9.","journal-title":"Nat Commun"},{"issue":"7","key":"4618_CR32","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nm.3893","volume":"21","author":"H Guo","year":"2015","unstructured":"Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015;21(7):677\u201387. https:\/\/doi.org\/10.1038\/nm.3893.","journal-title":"Nat Med"},{"issue":"2","key":"4618_CR33","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3390\/nu12020542","volume":"12","author":"EJ Park","year":"2020","unstructured":"Park EJ, Lee YS, Kim SM, Park GS, Lee YH, Jeong DY, et al. Beneficial effects of Lactobacillus plantarum strains on non-alcoholic fatty liver disease in high fat\/high fructose diet-fed rats. Nutrients. 2020;12(2):542. https:\/\/doi.org\/10.3390\/nu12020542.","journal-title":"Nutrients"},{"key":"4618_CR34","doi-asserted-by":"publisher","first-page":"106651","DOI":"10.1016\/j.vascn.2019.106651","volume":"101","author":"VS Jensen","year":"2020","unstructured":"Jensen VS, Tveden-Nyborg P, Zacho-Rasmussen C, Quaade ML, Ipsen DH, Hvid H, et al. Variation in diagnostic NAFLD\/NASH read-outs in paired liver samples from rodent models. J Pharmacol Toxicol Methods. 2020;101:106651.","journal-title":"J Pharmacol Toxicol Methods."},{"key":"4618_CR35","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1017\/S0007114520000380","volume":"123","author":"E Amabebe","year":"2020","unstructured":"Amabebe E, Robert FO, Agbalalah T, Orubu ES. Microbial dysbiosis-induced obesity: role of gut microbiota in homoeostasis of energy metabolism. Br J Nutr. 2020;123:1127\u201337.","journal-title":"Br J Nutr"},{"issue":"7","key":"4618_CR36","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","volume":"15","author":"A Tripathi","year":"2018","unstructured":"Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15(7):397\u201311. https:\/\/doi.org\/10.1038\/s41575-018-0011-z.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"14","key":"4618_CR37","doi-asserted-by":"publisher","first-page":"5843","DOI":"10.1007\/s00253-019-09703-4","volume":"103","author":"Z Zhao","year":"2019","unstructured":"Zhao Z, Wang C, Zhang L, Zhao Y, Duan C, Zhang X, et al. Lactobacillus plantarum NA136 improves the non-alcoholic fatty liver disease by modulating the AMPK\/Nrf2 pathway. Appl Microbiol Biotechnol. 2019;103(14):5843\u201350. https:\/\/doi.org\/10.1007\/s00253-019-09703-4.","journal-title":"Appl Microbiol Biotechnol"},{"issue":"24","key":"4618_CR38","doi-asserted-by":"publisher","first-page":"5212","DOI":"10.3390\/nu14245212","volume":"14","author":"JI Riezu-Boj","year":"2022","unstructured":"Riezu-Boj JI, Barajas M, P\u00e9rez-S\u00e1nchez T, Pajares MJ, Ara\u00f1a M, Milagro FI, et al. Lactiplantibacillus plantarum DSM20174 attenuates the progression of non-alcoholic fatty liver disease by modulating gut microbiota, improving metabolic risk factors, and attenuating adipose inflammation. Nutrients. 2022;14(24):5212. https:\/\/doi.org\/10.3390\/nu14245212.","journal-title":"Nutrients"},{"issue":"18","key":"4618_CR39","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.3390\/foods13182992","volume":"13","author":"J Lu","year":"2024","unstructured":"Lu J, Shataer D, Yan H, Dong X, Zhang M, Qin Y, et al. Probiotics and non-alcoholic fatty liver disease: unveiling the mechanisms of Lactobacillus plantarum and Bifidobacterium bifidum in modulating lipid metabolism, inflammation, and intestinal barrier integrity. Foods. 2024;13(18):2992. https:\/\/doi.org\/10.3390\/foods13182992.","journal-title":"Foods"},{"key":"4618_CR40","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/978-981-19-4492-5_9","volume-title":"Microbiome in gastrointestinal cancer","author":"Y Pan","year":"2023","unstructured":"Pan Y, Zhang X. Diet modulates gut microbiome and metabolites in non-alcoholic fatty liver diseases. In: Yu J, editor. Microbiome in gastrointestinal cancer. Singapore: Springer Nature Singapore; 2023. p. 131\u201346."},{"key":"4618_CR41","doi-asserted-by":"publisher","unstructured":"Shen S, Liu Y, Wang N, Huang Z, Deng G. The role of microbiota in nonalcoholic fatty liver disease: mechanism of action and treatment strategy. Front Microbiol. 2025;16. https:\/\/doi.org\/10.3389\/fmicb.2025.1621583.","DOI":"10.3389\/fmicb.2025.1621583"},{"issue":"2","key":"4618_CR42","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1136\/gutjnl-2015-309990","volume":"65","author":"JR Marchesi","year":"2016","unstructured":"Marchesi JR, Adams DH, Fava F, Hermes GDA, Hirschfield GM, Hold G, et al. The gut microbiota and host health: a new clinical frontier. Gut. 2016;65(2):330\u20139. https:\/\/doi.org\/10.1136\/gutjnl-2015-309990.","journal-title":"Gut"},{"key":"4618_CR43","doi-asserted-by":"publisher","first-page":"1129904","DOI":"10.3389\/fmicb.2023.1129904","volume":"14","author":"SJ Yoon","year":"2023","unstructured":"Yoon SJ, Yu JS, Min BH, Gupta H, Won SM, Park HJ, et al. Bifidobacterium-derived short-chain fatty acids and indole compounds attenuate nonalcoholic fatty liver disease by modulating gut-liver axis. Front Microbiol. 2023;14:1129904. https:\/\/doi.org\/10.3389\/fmicb.2023.1129904.","journal-title":"Front Microbiol"},{"issue":"1","key":"4618_CR44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.5114\/aoms.2016.62150","volume":"14","author":"V Nobili","year":"2018","unstructured":"Nobili V, Putignani L, Mosca A, Del Chierico F, Vernocchi P, Alisi A, et al. Bifidobacteria and lactobacilli in the gut microbiome of children with non-alcoholic fatty liver disease: which strains act as health players? Arch Med Sci. 2018;14(1):81\u20137. https:\/\/doi.org\/10.5114\/aoms.2016.62150.","journal-title":"Arch Med Sci"},{"key":"4618_CR45","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.phrs.2018.06.029","volume":"134","author":"J Boeckmans","year":"2018","unstructured":"Boeckmans J, Natale A, Buyl K, Rogiers V, De Kock J, Vanhaecke T, et al. Human-based systems: Mechanistic NASH modelling just around the corner? Pharmacol Res. 2018;134:257\u201367. https:\/\/doi.org\/10.1016\/j.phrs.2018.06.029.","journal-title":"Pharmacol Res"},{"issue":"1","key":"4618_CR46","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12866-021-02198-y","volume":"21","author":"A Koliada","year":"2021","unstructured":"Koliada A, Moseiko V, Romanenko M, Lushchak O, Kryzhanovska N, Guryanov V, et al. Sex differences in the phylum-level human gut microbiota composition. BMC Microbiol. 2021;21(1):131.","journal-title":"BMC Microbiol"},{"key":"4618_CR47","doi-asserted-by":"publisher","first-page":"67","DOI":"10.12938\/bmfh.18-001","volume":"37","author":"J Minami","year":"2018","unstructured":"Minami J, Iwabuchi N, Tanaka M, Yamauchi K, Xiao JZ, Abe F, et al. Effects of Bifidobacterium breve B-3 on body fat reductions in pre-obese adults: a randomized, double-blind, placebo-controlled trial. Biosci Microbiota Food Health. 2018;37:67\u201375. https:\/\/doi.org\/10.12938\/bmfh.18-001.","journal-title":"Biosci Microbiota Food Health"},{"issue":"7","key":"4618_CR48","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","volume":"27","author":"SA Harrison","year":"2021","unstructured":"Harrison SA, Ruane PJ, Freilich BL, Neff G, Patil R, Behling CA, et al. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. Nat Med. 2021;27(7):1262\u201371. https:\/\/doi.org\/10.1038\/s41591-021-01425-3.","journal-title":"Nat Med"},{"issue":"5","key":"4618_CR49","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1017\/S0007114520003001","volume":"125","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Zhou H, Zhou X, Sun J, Liang X, Lv Y, et al. Lactobacillus casei YRL577 ameliorates markers of non-alcoholic fatty liver and alters expression of genes within the intestinal bile acid pathway. Br J Nutr. 2021;125(5):521\u20139. https:\/\/doi.org\/10.1017\/S0007114520003001.","journal-title":"Br J Nutr"},{"key":"4618_CR50","doi-asserted-by":"publisher","first-page":"2264737","DOI":"10.1155\/2021\/2264737","volume":"2021","author":"M Luo","year":"2021","unstructured":"Luo M, Yan J, Wu L, Wu J, Chen Z, Jiang J, et al. Probiotics alleviated nonalcoholic fatty liver disease in high-fat diet-fed rats via gut microbiota\/FXR\/FGF15 signaling pathway. J Immunol Res. 2021;2021:2264737. https:\/\/doi.org\/10.1155\/2021\/2264737.","journal-title":"J Immunol Res"},{"issue":"12","key":"4618_CR51","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1007\/s10620-013-2879-3","volume":"58","author":"M Seo","year":"2013","unstructured":"Seo M, Inoue I, Tanaka M, Matsuda N, Nakano T, Awata T, et al. Clostridium butyricum MIYAIRI 588 improves high-fat diet-induced non-alcoholic fatty liver disease in rats. Dig Dis Sci. 2013;58(12):3534\u201344. https:\/\/doi.org\/10.1007\/s10620-013-2879-3.","journal-title":"Dig Dis Sci"},{"issue":"12","key":"4618_CR52","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1039\/c4fo00549j","volume":"5","author":"C Li","year":"2014","unstructured":"Li C, Nie SP, Zhu KX, Ding Q, Li C, Xiong T, et al. Lactobacillus plantarum NCU116 improves liver function, oxidative stress and lipid metabolism in rats with high fat diet induced non-alcoholic fatty liver disease. Food Funct. 2014;5(12):3216\u201323. https:\/\/doi.org\/10.1039\/c4fo00549j.","journal-title":"Food Funct"},{"issue":"11","key":"4618_CR53","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/j.1872-034X.2008.00382.x","volume":"38","author":"N Higuchi","year":"2008","unstructured":"Higuchi N, Kato M, Shundo Y, Tajiri H, Tanaka M, Yamashita N, et al. Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol Res. 2008;38(11):1122\u20139. https:\/\/doi.org\/10.1111\/j.1872-034X.2008.00382.x.","journal-title":"Hepatol Res"},{"issue":"7","key":"4618_CR54","doi-asserted-by":"publisher","first-page":"6528","DOI":"10.1039\/d0fo00180e","volume":"11","author":"D Zhao","year":"2020","unstructured":"Zhao D, Zhu H, Gao F, Qian Z, Mao W, Yin Y, et al. Antidiabetic effects of selenium-enriched Bifidobacterium longum DD98 in type 2 diabetes model of mice. Food Funct. 2020;11(7):6528\u201341. https:\/\/doi.org\/10.1039\/d0fo00180e.","journal-title":"Food Funct"},{"issue":"5","key":"4618_CR55","doi-asserted-by":"publisher","first-page":"e0051822","DOI":"10.1128\/spectrum.00518-22","volume":"10","author":"X Ye","year":"2022","unstructured":"Ye X, Huang D, Dong Z, Wang X, Ning M, Xia J, et al. FXR signaling-mediated bile acid metabolism is critical for alleviation of cholesterol gallstones by lactobacillus strains. Microbiol Spectr. 2022;10(5):e0051822. https:\/\/doi.org\/10.1128\/spectrum.00518-22.","journal-title":"Microbiol Spectr"},{"issue":"8","key":"4618_CR56","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.3390\/nu15082005","volume":"15","author":"JY Lee","year":"2023","unstructured":"Lee JY, An M, Heo H, Park JY, Lee J, Kang CH. Limosilactobacillus fermentum MG4294 and Lactiplantibacillus plantarum MG5289 ameliorates nonalcoholic fatty liver disease in high-fat diet-induced mice. Nutrients. 2023;15(8):2005. https:\/\/doi.org\/10.3390\/nu15082005.","journal-title":"Nutrients"},{"key":"4618_CR57","doi-asserted-by":"publisher","first-page":"11466","DOI":"10.3389\/fmicb.2023.114667272","volume":"14","author":"X Wen","year":"2023","unstructured":"Wen X, Liu H, Luo X, Lui L, Fan J, Xing Y, et al. Supplementation of Lactobacillus plantarum ATCC14917 mitigates non-alcoholic fatty liver disease in high-fat-diet-fed rats. Front Microbiol. 2023;14:11466. https:\/\/doi.org\/10.3389\/fmicb.2023.114667272.","journal-title":"Front Microbiol"},{"key":"4618_CR58","doi-asserted-by":"publisher","first-page":"1071284","DOI":"10.3389\/fnut.2022.1071284","volume":"9","author":"F Cao","year":"2022","unstructured":"Cao F, Ding Q, Zhuge H, Lai S, Chang K, Le C, et al. Lactobacillus plantarum ZJUIDS14 alleviates non-alcoholic fatty liver disease in mice in association with modulation in the gut microbiota. Front Nutr. 2022;9:1071284. https:\/\/doi.org\/10.3389\/fnut.2022.1071284.","journal-title":"Front Nutr"},{"issue":"1","key":"4618_CR59","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1177\/1099800420942942","volume":"23","author":"AS Machado","year":"2021","unstructured":"Machado AS, Oliveira R, Lelis DF, de Paula AMB, Guimar\u00e3es ALS, Andrade JMO, et al. Oral Probiotic Bifidobacterium Longum Supplementation Improves Metabolic Parameters and Alters the Expression of the Renin-Angiotensin System in Obese Mice Liver. Biol Res Nurs. 2021;23(1):100\u20138. https:\/\/doi.org\/10.1177\/1099800420942942.","journal-title":"Biol Res Nurs."},{"issue":"2","key":"4618_CR60","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bbrc.2016.10.031","volume":"480","author":"Z Li","year":"2016","unstructured":"Li Z, Jin H, Oh SY, Ji GE. Anti-obese effects of two Lactobacilli and two Bifidobacteria on ICR mice fed on a high fat diet. Biochem Biophys Res Commun Biochem Biophys Res Commun. 2016;480(2):222\u20137. https:\/\/doi.org\/10.1016\/j.bbrc.2016.10.031.","journal-title":"Biochem Biophys Res Commun Biochem Biophys Res Commun"},{"key":"4618_CR61","doi-asserted-by":"publisher","first-page":"469059","DOI":"10.1155\/2014\/469059","volume":"2014","author":"T Ren","year":"2014","unstructured":"Ren T, Huang C, Cheng M. Dietary blueberry and bifidobacteria attenuate nonalcoholic fatty liver disease in rats by affecting SIRT1-mediated signaling pathway. Oxid Med Cell Longev. 2014;2014:469059. https:\/\/doi.org\/10.1155\/2014\/469059.","journal-title":"Oxid Med Cell Longev"},{"issue":"9","key":"4618_CR62","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.3390\/nu14091965","volume":"14","author":"OhMJ DoMH","year":"2022","unstructured":"DoMH OhMJ, Lee HB, Kang CH, Yoo G, Park HY, et al. Bifidobacterium animalis ssp. lactis MG741 Reduces Body Weight and Ameliorates Nonalcoholic Fatty Liver Disease via Improving the Gut Permeability and Amelioration of Inflammatory Cytokines. Nutrients. 2022;14(9):1965. https:\/\/doi.org\/10.3390\/nu14091965.","journal-title":"Nutrients."},{"issue":"1","key":"4618_CR63","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13568-020-01038-y","volume":"10","author":"Y Yan","year":"2020","unstructured":"Yan Y, Liu C, Zhao S, Wang X, Wang J, Zhang H, et al. Probiotic Bifidobacterium lactis V9 attenuates hepatic steatosis and inflammation in rats with non-alcoholic fatty liver disease. AMB Express. 2020;10(1):101. https:\/\/doi.org\/10.1186\/s13568-020-01038-y.","journal-title":"AMB Express"},{"key":"4618_CR64","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s40168-022-01374-0","volume":"10","author":"G Kim","year":"2022","unstructured":"Kim G, Yoon Y, Park JH, Park JW, Noh MG, Kim H, et al. Bifidobacterial carbohydrate\/nucleoside metabolism enhances oxidative phosphorylation in white adipose tissue to protect against diet-induced obesity. Microbiome. 2022;10:188. https:\/\/doi.org\/10.1186\/s40168-022-01374-0.","journal-title":"Microbiome"},{"issue":"5","key":"4618_CR65","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1017\/S0007114517000204","volume":"117","author":"F Mofidi","year":"2017","unstructured":"Mofidi F, Poustchi H, Yari Z, Nourinayyer B, Merat S, Sharafkhah M, et al. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. Br J Nutr. 2017;117(5):662\u20138. https:\/\/doi.org\/10.1017\/S0007114517000204.","journal-title":"Br J Nutr"},{"issue":"3","key":"4618_CR66","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/MPG.0000000000001422","volume":"64","author":"F Famouri","year":"2017","unstructured":"Famouri F, Shariat Z, Hashemipour M, Keikha M, Kelishadi R. Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents. J Pediatr Gastroenterol Nutr. 2017;64(3):413\u20137. https:\/\/doi.org\/10.1097\/MPG.0000000000001422.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"4618_CR67","doi-asserted-by":"publisher","first-page":"5688","DOI":"10.1038\/s41598-019-42059-3","volume":"9","author":"B Ahn","year":"2019","unstructured":"Ahn B, Won Jun D, Kang BK, Lim JH, Lim S, Chung M-J, et al. Randomized, Double-blind, placebo-controlled study of a Multispecies probiotic Mixture in Nonalcoholic Fatty Liver Disease. SciRep. 2019;9(1):5688. https:\/\/doi.org\/10.1038\/s41598-019-42059-3.","journal-title":"SciRep"},{"key":"4618_CR68","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41387-024-00281-7","volume":"14","author":"A Vakilpour","year":"2024","unstructured":"Vakilpour A, Amini-Salehi E, Soltani Moghadam A, et al. The effects of gut microbiome manipulation on glycemic indices in patients with non-alcoholic fatty liver disease: a comprehensive umbrella review. Nutr Diabetes. 2024;14:25. https:\/\/doi.org\/10.1038\/s41387-024-00281-7.","journal-title":"Nutr Diabetes"},{"issue":"12","key":"4618_CR69","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1080\/17474124.2022.2016391","volume":"15","author":"YY Ma","year":"2013","unstructured":"Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM, et al. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 2013;15(12):1401\u20139. https:\/\/doi.org\/10.1080\/17474124.2022.2016391.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"4618_CR70","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3945\/ajcn.113.068890","volume":"99","author":"T Eslamparast","year":"2014","unstructured":"Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 2014;99(3):535\u201342. https:\/\/doi.org\/10.3945\/ajcn.113.068890.","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"4618_CR71","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1084\/jem.20171965","volume":"215","author":"H Shapiro","year":"2018","unstructured":"Shapiro H, Kolodziejczyk AA, Halstuch D, Elinav E. Bile acids in glucose metabolism in health and disease. J Exp Med. 2018;215(2):383\u201396. https:\/\/doi.org\/10.1084\/jem.20171965.","journal-title":"J Exp Med"},{"issue":"5","key":"4618_CR72","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1017\/S0007114520003001","volume":"125","author":"X Zhou","year":"2021","unstructured":"Zhou X, Sun J, Liang X, Lv Y, Bai L, Zhang J, et al. Lactobacillus casei YRL577 ameliorates markers of non-alcoholic fatty liver and alters expression of genes within the intestinal bile acid pathway. BrJNutr. 2021;125(5):521\u20139. https:\/\/doi.org\/10.1017\/S0007114520003001.","journal-title":"BrJNutr"},{"issue":"8","key":"4618_CR73","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1002\/fsn3.1118","volume":"7","author":"W Wang","year":"2019","unstructured":"Wang W, Li Q, Chai W, Sun C, Zhang T, Zhao C, et al. Lactobacillus paracasei Jlus66 extenuate oxidative stress and inflammation via regulation of intestinal flora in rats with non alcoholic fatty liver disease. Food Sci Nutr. 2019;7(8):2636\u201346. https:\/\/doi.org\/10.1002\/fsn3.1118.","journal-title":"Food Sci Nutr"},{"issue":"5","key":"4618_CR74","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/lam.13360","volume":"71","author":"K Dev","year":"2020","unstructured":"Dev K, Akbar Mir N, Biswas A, Kannoujia J, Begum J, Kant R. Dietary mannan-oligosaccharides potentiate the beneficial effects of Bifidobacterium bifidum in broiler chicken. Lett Appl Microbiol. 2020;71(5):520\u201330. https:\/\/doi.org\/10.1111\/lam.13360.","journal-title":"Lett Appl Microbiol"},{"issue":"9","key":"4618_CR75","first-page":"1090","volume":"15","author":"R Aller","year":"2011","unstructured":"Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 2011;15(9):1090\u20135.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"6","key":"4618_CR76","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1093\/ajcn\/nqy358","volume":"109","author":"Y Chen","year":"2019","unstructured":"Chen Y, Feng R, Yang X, Dai J, Huang M, Ji X, et al. Yogurt improves insulin resistance and liver fat in obese women with nonalcoholic fatty liver disease and metabolic syndrome: a randomized controlled trial. Am J Clin Nutr. 2019;109(6):1611\u20139. https:\/\/doi.org\/10.1093\/ajcn\/nqy358.","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"4618_CR77","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s10620-011-1887-4","volume":"57","author":"M Malaguarnera","year":"2012","unstructured":"Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci. 2012;57(2):545\u201353. https:\/\/doi.org\/10.1007\/s10620-011-1887-4.","journal-title":"Dig Dis Sci"},{"issue":"8","key":"4618_CR78","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1093\/jn\/nxy088","volume":"148","author":"F Bakhshimoghaddam","year":"2018","unstructured":"Bakhshimoghaddam F, Shateri K, Sina M, Hashemian M, Alizadeh M. Daily consumption of synbiotic yogurt decreases liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled clinical trial. J Nutr. 2018;148(8):1276\u201384.","journal-title":"J Nutr"},{"issue":"1","key":"4618_CR79","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13568-020-01038-y","volume":"10","author":"Y Yan","year":"2020","unstructured":"Yan Y, Chunyan L, Shimin Z, Xinxu W, Jinling W, Heping Z, et al. Probiotic Bifidobacterium lactis V9 attenuates hepatic steatosis and inflammation in rats with non-alcoholic fatty liver disease. AMB Express (springer Open). 2020;10(1):101. https:\/\/doi.org\/10.1186\/s13568-020-01038-y.","journal-title":"AMB Express (springer Open)"},{"issue":"4","key":"4618_CR80","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/dom.12861","volume":"19","author":"R Mobini","year":"2017","unstructured":"Mobini R, Tremaroli V, St\u00e5hlman M, Karlsson F, Levin M, Ljungberg M, et al. Metabolic effects of Lactobacillus reuteri DSM 17938 in people with type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2017;19(4):579\u201389. https:\/\/doi.org\/10.1111\/dom.12861.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"4618_CR81","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/nrendo.2014.60","volume":"10","author":"F Kuipers","year":"2014","unstructured":"Kuipers F, Bloks VW, Groen AK. Beyond intestinal soap\u2014bile acids in metabolic control. Nat Rev Endocrinol. 2014;10(8):488\u201398. https:\/\/doi.org\/10.1038\/nrendo.2014.60.","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"4618_CR82","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1177\/1756283X16645055","volume":"9","author":"D Briskey","year":"2016","unstructured":"Briskey D, Heritage M, Jaskowski LA, Peake J, Gobe G, Subramaniam VN, et al. Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease. Ther Adv Gastroenterol. 2016;9(4):463\u201372. https:\/\/doi.org\/10.1177\/1756283X16645055.","journal-title":"Ther Adv Gastroenterol"},{"issue":"1","key":"4618_CR83","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12906-016-1540-z","volume":"17","author":"HM Al-muzafar","year":"2017","unstructured":"Al-muzafar HM, Amin KA. Probiotic mixture improves fatty liver disease by virtue of its action on lipid profiles, leptin, and inflammatory biomarkers. BMC Complement Altern Med. 2017;17(1):43. https:\/\/doi.org\/10.1186\/s12906-016-1540-z.","journal-title":"BMC Complement Altern Med"},{"key":"4618_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.29219\/fnr.v65.8087","volume":"65","author":"SI Choi","year":"2021","unstructured":"Choi SI, You S, Kim S, Won G, Kang CH, Kim GH. Weissella cibaria MG5285 and Lactobacillus reuteri MG5149 attenuated fat accumulation in adipose and hepatic steatosis in high-fat diet-induced C57BL\/6J obese mice. Food Nutr Res. 2021;65:1\u201311. https:\/\/doi.org\/10.29219\/fnr.v65.8087.","journal-title":"Food Nutr Res"},{"key":"4618_CR85","doi-asserted-by":"publisher","first-page":"101109","DOI":"10.1016\/j.plipres.2021.101109","volume":"83","author":"H Li","year":"2021","unstructured":"Li H, Yu XH, Ou X, Ouyang XP, Tang CK. Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis. Prog Lipid Res. 2021;83:101109. https:\/\/doi.org\/10.1016\/j.plipres.2021.101109.","journal-title":"Prog Lipid Res"},{"key":"4618_CR86","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.fct.2017.04.045","volume":"107","author":"X Bian","year":"2017","unstructured":"Bian X, Tu P, Chi L, Gao B, Ru H, Lu K. Saccharin induced liver inflammation in mice by altering the gut microbiota and its metabolic functions. Food Chem Toxicol. 2017;107:530\u20139. https:\/\/doi.org\/10.1016\/j.fct.2017.04.045.","journal-title":"Food Chem Toxicol"},{"issue":"39","key":"4618_CR87","doi-asserted-by":"publisher","first-page":"41434","DOI":"10.18632\/oncotarget.5163","volume":"6","author":"S Ceccarelli","year":"2015","unstructured":"Ceccarelli S, Panera N, Mina M, Gnani D, De Stefanis C, Crudele A, et al. LPS-induced TNF-\u03b1 factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease. Oncotarget. 2015;6(39):41434\u201352. https:\/\/doi.org\/10.18632\/oncotarget.5163.","journal-title":"Oncotarget"},{"issue":"10","key":"4618_CR88","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.3390\/nu9101156","volume":"9","author":"A Llewellyn","year":"2017","unstructured":"Llewellyn A, Foey A. Probiotic Modulation of Innate Cell Pathogen Sensing and Signaling Events. Nutrients. 2017;9(10):1156. https:\/\/doi.org\/10.3390\/nu9101156.","journal-title":"Nutrients"},{"issue":"1","key":"4618_CR89","doi-asserted-by":"publisher","first-page":"41","DOI":"10.15403\/jgld.2014.1121.271.kby","volume":"27","author":"N Kobyliak","year":"2018","unstructured":"Kobyliak N, Abenavoli L, Mykhalchyshyn G, Kononenko L, Boccuto L, Kyriienko D, et al. A Multi-strain Probiotic Reduces the Fatty Liver Index, Cytokines and Aminotransferase levels in NAFLD Patients: Evidence from a Randomized Clinical Trial. J Gastrointestin Liver Dis. 2018;27(1):41\u20139. https:\/\/doi.org\/10.15403\/jgld.2014.1121.271.kby.","journal-title":"J Gastrointestin Liver Dis."},{"issue":"4","key":"4618_CR90","first-page":"763","volume":"11","author":"F Nian","year":"2023","unstructured":"Nian F, Wu L, Xia Q, Tian P, Ding C, Lu X, et al. Akkermansia muciniphila\u00a0and\u00a0Bifidobacterium bifidum\u00a0Prevent NAFLD by Regulating FXR Expression and Gut Microbiota. J Clin Transl Hepatol. 2023;11(4):763\u201376.","journal-title":"J Clin Transl Hepatol."},{"key":"4618_CR91","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12934-022-01840-2","volume":"21","author":"S Kang","year":"2022","unstructured":"Kang S, Lin Z, Xu Y, et al. A recombinant Bifidobacterium bifidum BGN4 strain expressing the streptococcal superoxide dismutase gene ameliorates inflammatory bowel disease. Microb Cell Fact. 2022;21:113. https:\/\/doi.org\/10.1186\/s12934-022-01840-2.","journal-title":"Microb Cell Fact"},{"key":"4618_CR92","doi-asserted-by":"publisher","first-page":"18507","DOI":"10.1038\/srep18507","volume":"6","author":"O Rossi","year":"2016","unstructured":"Rossi O, van Berkel LA, Chain F, Khan MT, Taverne N, Sokol H, et al. Faecalibacterium prausnitzii A2\u2013165 has a high capacity to induce IL-10 in human and murine dendritic cells and modulates T cell responses. Sci Rep. 2016;6:18507. https:\/\/doi.org\/10.1038\/srep18507.","journal-title":"Sci Rep"},{"issue":"2","key":"4618_CR93","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1053\/j.gastro.2020.03.010","volume":"159","author":"CR Naudin","year":"2020","unstructured":"Naudin CR, Maner-Smith K, Owens JA, Wynn GM, Robinson BS, Matthews JD, et al. Lactococcus lactis subspecies cremoris elicits protection against metabolic changes induced by a western-style diet. Gastroenterology. 2020;159(2):639-651.e5. https:\/\/doi.org\/10.1053\/j.gastro.2020.03.010.","journal-title":"Gastroenterology"},{"issue":"6","key":"4618_CR94","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41575-020-00411-3","volume":"18","author":"J Gracia-Sancho","year":"2021","unstructured":"Gracia-Sancho J, Caparr\u00f3s E, Fern\u00e1ndez-Iglesias A, Franc\u00e9s R. Role of liver sinusoidal endothelial cells in liver diseases. Nat Rev Gastroenterol Hepatol. 2021;18(6):411\u201331. https:\/\/doi.org\/10.1038\/s41575-020-00411-3.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4618_CR95","doi-asserted-by":"publisher","first-page":"9351507","DOI":"10.1155\/2017\/9351507","volume":"2017","author":"G Rizzatti","year":"2017","unstructured":"Rizzatti G, Lopetuso LR, Gibiino G, Binda C, Gasbarrini A. Proteobacteria: a common factor in human diseases. BioMed Res Int. 2017;2017:9351507. https:\/\/doi.org\/10.1155\/2017\/9351507.","journal-title":"BioMed Res Int"},{"issue":"5Suppl","key":"4618_CR96","doi-asserted-by":"publisher","first-page":"14S","DOI":"10.1177\/0148607111413772","volume":"35","author":"H FrazierT","year":"2011","unstructured":"FrazierT H, DiBaise JK, McClain CJ. Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury. JPEN J Parenter Enteral Nutr. 2011;35(5Suppl):14S-20S. https:\/\/doi.org\/10.1177\/0148607111413772.","journal-title":"JPEN J Parenter Enteral Nutr."},{"key":"4618_CR97","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1080\/07315724.2015.1031355","volume":"35","author":"A Sepideh","year":"2016","unstructured":"Sepideh A, Karim P, Hossein A, Leila R, Hamdollah M, Mohammad EG, et al. Effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease: a double-blind randomized clinical trial. J Am Coll Nutr. 2016;35:500\u20135 Epub 2011 Aug 1.","journal-title":"J Am Coll Nutr."},{"issue":"7","key":"4618_CR98","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1007\/s11427-017-9303-9","volume":"61","author":"F Li","year":"2018","unstructured":"Li F, Sun G, Wang Z, Wu W, Guo H, Peng L, et al. Characteristics of fecal microbiota in non-alcoholic fatty liver disease patients. Sci China Life Sci. 2018;61(7):770\u20138. https:\/\/doi.org\/10.1007\/s11427-017-9303-9.","journal-title":"Sci China Life Sci"},{"issue":"5","key":"4618_CR99","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.fshw.2022.04.034","volume":"11","author":"C Tang","year":"2022","unstructured":"Tang C, Zhou W, Shan M, Lu Z, Lu Y. Yogurt-derived Lactobacillus plantarum Q16 alleviated high-fat diet-induced non-alcoholic fatty liver disease in mice. Food Sci Hum Wellness. 2022;11(5):1428\u201339. https:\/\/doi.org\/10.1016\/j.fshw.2022.04.034.","journal-title":"Food Sci Hum Wellness"},{"issue":"1","key":"4618_CR100","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13059-017-1194-2","volume":"18","author":"E Org","year":"2017","unstructured":"Org E, Blum Y, Kasela S, Mehrabian M, Kuusisto J, Kangas A, et al. Relationships between gut microbiota, plasma metabolites, and metabolic syndrome traits in the METSIM cohort. Genome Biol. 2017;18(1):70. https:\/\/doi.org\/10.1186\/s13059-017-1194-2.","journal-title":"Genome Biol"},{"key":"4618_CR101","doi-asserted-by":"publisher","first-page":"997018","DOI":"10.3389\/fcimb.2022.997018","volume":"12","author":"J Fang","year":"2022","unstructured":"Fang J, Yu CH, Li XJ, Yao JM, Fang ZY, Yoon SH, et al. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications. Front Cell Infect Microbiol. 2022;12:997018.","journal-title":"Front Cell Infect Microbiol"},{"issue":"22","key":"4618_CR102","doi-asserted-by":"publisher","first-page":"6034","DOI":"10.1080\/10408398.2021.1895064","volume":"62","author":"A Rauf","year":"2022","unstructured":"Rauf A, Khalil AA, Rahman UU, Khalid A, Naz S, Shariati MA, et al. Recent advances in the therapeutic application of short-chain fatty acids (SCFAs): an updated review. Crit Rev Food Sci Nutr. 2022;62(22):6034\u201354. https:\/\/doi.org\/10.1080\/10408398.2021.1895064.","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"4","key":"4618_CR103","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.3390\/nu14142945","volume":"14","author":"W Hu","year":"2022","unstructured":"Hu W, Gao W, Liu Z, Fang Z, Wang H, Zhao J, et al. Specific Strains of Faecalibacterium prausnitzii Ameliorate Nonalcoholic Fatty Liver Disease in Mice in Association with Gut Microbiota Regulation. Nutrients. 2022;14(4):2945. https:\/\/doi.org\/10.3390\/nu14142945.","journal-title":"Nutrients"},{"issue":"8","key":"4618_CR104","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.3390\/nu11081712","volume":"11","author":"Y Ji","year":"2019","unstructured":"Ji Y, Yin Y, Li Z, Zhang W. Gut microbiota-derived components and metabolites in the progression of non-alcoholic fatty liver disease (NAFLD). Nutrients. 2019;11(8):1712. https:\/\/doi.org\/10.3390\/nu11081712.","journal-title":"Nutrients"},{"issue":"6","key":"4618_CR105","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s11892-015-0607-4","volume":"15","author":"C Saponaro","year":"2015","unstructured":"Saponaro C, Gaggini M, Gastaldelli A. Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms. Curr Diab Rep. 2015;15(6):607. https:\/\/doi.org\/10.1007\/s11892-015-0607-4.","journal-title":"Curr Diab Rep"},{"issue":"19","key":"4618_CR106","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.3390\/ijerph16193570","volume":"16","author":"V Kup\u010dov\u00e1","year":"2019","unstructured":"Kup\u010dov\u00e1 V, Fedele\u0161ov\u00e1 M, Bulas J, Kozmo nova P, Tureck\u00fd L. Overview of the pathogenesis, genetic, and non-invasive clinical, biochemical, and scoring methods in the assessment of NAFLD. Int J Environ Res Public Health. 2019;16(19):3570. https:\/\/doi.org\/10.3390\/ijerph16193570.","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"4618_CR107","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s40168-023-01709-5","volume":"11","author":"H Xu","year":"2023","unstructured":"Xu H, Fang F, Wu K, Song J, Li Y, Lu X, et al. Gut microbiota-bile acid crosstalk regulates murine lipid metabolism via the intestinal FXR-FGF19 axis in diet-induced humanized dyslipidemia. Microbiome. 2023;11(1):262. https:\/\/doi.org\/10.1186\/s40168-023-01709-5.","journal-title":"Microbiome."},{"key":"4618_CR108","doi-asserted-by":"publisher","first-page":"1087260","DOI":"10.3389\/fendo.2022.1087260","volume":"13","author":"L Rong","year":"2022","unstructured":"Rong L, Zou J, Ran W, Qi X, Chen Y, Cui H, et al. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol (Lausanne). 2022;13:1087260. https:\/\/doi.org\/10.3389\/fendo.2022.1087260.","journal-title":"Front Endocrinol (Lausanne)."},{"key":"4618_CR109","doi-asserted-by":"publisher","first-page":"710420","DOI":"10.3389\/fphys.2021.710420","volume":"12","author":"Q Lu","year":"2021","unstructured":"Lu Q, Tian X, Wu H, Huang J, Li M, Mei Z, et al. Metabolic changes of hepatocytes in NAFLD. Front Physiol. 2021;12:710420. https:\/\/doi.org\/10.3389\/fphys.2021.710420.","journal-title":"Front Physiol"},{"issue":"4","key":"4618_CR110","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3390\/fermentation9040395","volume":"9","author":"M Monserrat-Mesquida","year":"2023","unstructured":"Monserrat-Mesquida M, Bouzas C, Mascar\u00f3 CM, Tejada S, Sureda A. Probiotics as potential therapy in the management of non-alcoholic fatty liver disease (NAFLD). Fermentation. 2023;9(4):395. https:\/\/doi.org\/10.3390\/fermentation9040395.","journal-title":"Fermentation"},{"issue":"4","key":"4618_CR111","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3390\/biology13040243","volume":"13","author":"C Long","year":"2024","unstructured":"Long C, Zhou X, Xia F, Zhou B. Intestinal barrier dysfunction and gut microbiota in non-alcoholic fatty liver disease: assessment, mechanisms, and therapeutic considerations. Biology. 2024;13(4):243. https:\/\/doi.org\/10.3390\/biology13040243.","journal-title":"Biology"},{"key":"4618_CR112","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3389\/fmicb.2016.00925","volume":"7","author":"A O\u2019Callaghan","year":"2016","unstructured":"O\u2019Callaghan A, Van Sinderen D. Bifidobacteria and their role as members of the human gut microbiota. Front Microbiol Front Microbiol. 2016;7:925. https:\/\/doi.org\/10.3389\/fmicb.2016.00925.","journal-title":"Front Microbiol Front Microbiol"},{"issue":"1","key":"4618_CR113","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3350\/cmh.2020.0298","volume":"27","author":"TY Ren","year":"2021","unstructured":"Ren TY, Li XY, Fan JG. Probiotics for treatment of nonalcoholic fatty liver disease: it is worth a try. Clin Mol Hepatol. 2021;27(1):83\u20136. https:\/\/doi.org\/10.3350\/cmh.2020.0298.","journal-title":"Clin Mol Hepatol"},{"key":"4618_CR114","doi-asserted-by":"publisher","first-page":"1014670","DOI":"10.3389\/fendo.2022.1014670","volume":"13","author":"Q Wang","year":"2022","unstructured":"Wang Q, Wang Z, Pang B, Zheng H, Cao Z, Feng C, et al. Probiotics for the improvement of metabolic profiles in patients with metabolic-associated fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2022;13:1014670. https:\/\/doi.org\/10.3389\/fendo.2022.1014670.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10165","key":"4618_CR115","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","volume":"392","author":"A Sanyal","year":"2018","unstructured":"Sanyal A, Charles ED, Neuschwander-Tetri BA, Loomba R, Harrison SA, Abdelmalek MF, et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet. 2018;392(10165):2705\u201317.","journal-title":"Lancet"},{"issue":"21","key":"4618_CR116","doi-asserted-by":"publisher","first-page":"13436","DOI":"10.3390\/ijms232113436","volume":"23","author":"HT Nguyen","year":"2022","unstructured":"Nguyen HT, Gu M, Werlinger P, Cho JH, Cheng J, Suh JW, et al. Lactobacillus sakei MJM60958 as a potential probiotic alleviated non-alcoholic fatty liver disease in mice fed a high-fat diet by modulating lipid metabolism, inflammation, and gut microbiota. Int J Mol Sci. 2022;23(21):13436. https:\/\/doi.org\/10.3390\/ijms232113436.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"4618_CR117","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.3390\/microorganisms10112203","volume":"10","author":"P Werlinger","year":"2022","unstructured":"Werlinger P, Nguyen HT, Gu M, Cho JH, Cheng J, Suh J-W. Lactobacillus reuteri MJM60668 prevent progression of non-alcoholic fatty liver disease through anti-adipogenesis and anti-inflammatory pathway. Microorganisms. 2022;10(11):2203. https:\/\/doi.org\/10.3390\/microorganisms10112203.","journal-title":"Microorganisms"},{"issue":"6","key":"4618_CR118","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1039\/C9FO03003D","volume":"11","author":"M Chen","year":"2020","unstructured":"Chen M, Guo WL, Li QY, Xu JX, Cao YJ, Liu B, et al. The protective mechanism of Lactobacillus plantarum FZU3013 against non-alcoholic fatty liver associated with hyperlipidemia in mice fed a high-fat diet. Food Funct. 2020;11(6):3316\u201331. https:\/\/doi.org\/10.1039\/C9FO03003D.","journal-title":"Food Funct"},{"key":"4618_CR119","doi-asserted-by":"publisher","first-page":"1617805","DOI":"10.1155\/2020\/1617805","volume":"19","author":"A Gonzalez","year":"2020","unstructured":"Gonzalez A, Huerta-Salgado C, Orozco-Aguilar J, Aguirre F, Tacchi F, Simon F, et al. Role of oxidative stress in hepatic and extrahepatic dysfunctions during nonalcoholic fatty liver disease (NAFLD). Oxid Med Cell Longev. 2020;19:1617805. https:\/\/doi.org\/10.1155\/2020\/1617805.","journal-title":"Oxid Med Cell Longev"},{"issue":"13","key":"4618_CR120","doi-asserted-by":"publisher","first-page":"5944","DOI":"10.3390\/ijms26135944","volume":"26","author":"KS Chang","year":"2025","unstructured":"Chang KS, Kuo WH, Chang MH, Hsiao Y, Tsai RY. Gut microbiota and liver health: meta-analysis of Bifidobacterium-containing probiotics in NAFLD management. Int J Mol Sci. 2025;26(13):5944. https:\/\/doi.org\/10.3390\/ijms26135944.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4618_CR121","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1084\/jem.20171965","volume":"215","author":"H Shapiro","year":"2018","unstructured":"Shapiro H, Kolodziejczyk AA, Halstuch D, Elinav E. Bile acids in glucose metabolism in health and disease. J Exp Med. 2018;215(2):383\u201396. https:\/\/doi.org\/10.1084\/jem.20171965.","journal-title":"J Exp Med."},{"issue":"7","key":"4618_CR122","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/j.celrep.2016.10.041","volume":"17","author":"A Picard","year":"2016","unstructured":"Picard A, Soyer J, Berney X, Tarussio D, Quenneville S, Jan M, et al. A genetic screen identifies hypothalamic Fgf15 as a regulator of glucagon secretion. Cell Rep. 2016;17(7):1795\u2013806. https:\/\/doi.org\/10.1016\/j.celrep.2016.10.041.","journal-title":"Cell Rep"},{"issue":"3","key":"4618_CR123","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jhep.2016.04.018","volume":"65","author":"G Marrone","year":"2016","unstructured":"Marrone G, Shah VH, Gracia-Sancho J. Sinusoidal communication in liver fibrosis and regeneration. J Hepatol. 2016;65(3):608\u201317. https:\/\/doi.org\/10.1016\/j.jhep.2016.04.018.","journal-title":"J Hepatol"},{"issue":"8","key":"4618_CR124","doi-asserted-by":"publisher","first-page":"e0161635","DOI":"10.1371\/journal.pone.0161635","volume":"11","author":"X Ling","year":"2016","unstructured":"Ling X, Linglong P, Weixia D, Hong W. Protective effects of Bifidobacterium on intestinal barrier function in LPS-induced enterocyte barrier injury of Caco-2 monolayers and in a rat NEC model. PLoS One. 2016;11(8):e0161635. https:\/\/doi.org\/10.1371\/journal.pone.0161635.","journal-title":"PLoS One"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04618-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04618-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04618-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T10:51:12Z","timestamp":1772621472000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04618-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":124,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4618"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04618-7","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"24 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"156"}}